Blue Horseshoe Stocks

ARNA, VHGI, EVDR, TWHI & Today’s Extended Watchlist

Arena Pharmaceuticals, Inc. ARNA

With only a couple of sessions remaining before ARNA’s FDA date, we are watching this stock as closely as ever. We expect to see a significant amount of volatility from the stock this week, as we keep our eyes peeled for new press.

No matter how this all shakes out, we will want to keep ARNA on a short leash heading into the FDA date, as there are no guarantees to its performance, FDA approval or not. As we stated on Friday, smart traders may have already taken some profits off of the table.

VHGI Holdings, Inc. VHGI

We first mentioned VHGI on December 9th, and on that day, we saw a great run totaling nearly 100% from .21-.40. By January the 23rd, that high increased nearly two-fold again, running up to .746.

On Friday the stock saw abnormally high volume coupled with the 52-week low, prompting us to put VHGI back on our watchlist in anticipation of an eventual bounce. All in all, we feel the recent selloff as a new opportunity with this stock.

Evader, Inc. EVDR

We first alerted EVDR on May 2nd. On May 3rd, it hit a high of .003, yielding us a rapid 150% overnight gain!

We have witnessed EVDR’s ability to make significant leaps in just a short time period, and will thus be monitoring closely for the next wave of activity.

Thwapr, Inc. THWI

Although THWI didnt put up the performance we hoped for last week, it did hold support at .026

We noticed some newsletter coverage over the weekend from various emailers, and look forward to seeing the actvity resulting from heightened awareness.

Extended Watchlist:

ECDC, PROP, VPER, BKW,

Arena Pharmaceuticals, Inc. – ARNA & Today’s Extended Watchlist

Arena Pharmaceuticals, Inc. ARNA

ARNA has been on an unstoppable run since we’ve had it appear in our newsletters. Even in uncertain times with the market, with the Dow being down more than 200pts yesterday, ARNA continued to push forward, gaining another 11%

That brings the total gain we’ve pulled in from ARNA to 112% in just over a month’s time. There are certainly no guarantees that ARNA will receive the FDA approval that everyone seems to be anticipating. Some would say now is the time to lock in those profits before the results are in, for failure to attain FDA approval could send this stock into a downward spiral.

We’ve even considered the idea of playing puts on ARNA options should things get a little ugly from here. $5 & $7 Puts would be multi-bag winners if the stock should fall to the 2.00 range, a distinct possibility if FDA approval isn’t awarded.

On the flipside, straddling the stock by purchasing both a Call and a Put could mitigate our risk in the event that FDA approval is forthcoming. For example, the $15 Calls were trading at .83 yesterday, and the $5 Puts closed at .38. ($7 closed @ .65) which will be even cheaper if the stock gaps up this morning as it appears to be doing.

___

Extended Watchlist:

THWI, USNL, EEDG, RENU

RENU – Renuen Corp. & Today’s Extended Watchlist

Renuen Corp RENU

RENU has appeared in our newsletter and on our extended watchlist over the past couple of months.

In May, we saw it run from a low of .0016 to a high of .0073, for a 356% gain. Following that run, we experienced a consolidation, where RENU found support in the low .002’s.

Yesterday the stock began to perk its head up, hitting a high of .004. The key to the session was the breaking of the 50 & 100DMA, (.0033 & .0034).

RENU is receiving a “Buy” Rating from Barchart.com

We feel that the indicators are setting up the possibility for another big run, so we will want to remain vigilant, and keep RENU on our radars.

____